Sugi Predict

Sugi Predict / Compounds / Pacritinib

Pacritinib

Pacritinib

SCHEMBL2336009

C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACVR1FLT3IRAK1JAK2

The experimentally established mechanism targets of Pacritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 known ✓ O60674 18/20 0.83
▸ FLT3 known ✓ P36888 15/20 0.83
▸ IRAK1 known ✓ P51617 1/20 0.83
▸ ACVR1 known ✓ Q04771 1/20 0.83
▸ TYK2 P29597 13/20 0.83
▸ CDK2 P24941 11/20 0.83
▸ CCNA2 P20248 10/20 0.83
▸ JAK1 P23458 10/20 0.83
▸ CCNA1 P78396 10/20 0.83
▸ JAK3 P52333 9/20 0.83
▸ CYP2D6 P10635 2/20 0.83
▸ GAK O14976 1/20 0.83
▸ STK16 O75716 1/20 0.83
▸ STK10 O94804 1/20 0.83
▸ MAP4K4 O95819 1/20 0.83
▸ PRKCB P05771 1/20 0.83
▸ LCK P06239 1/20 0.83
▸ CSF1R P07333 1/20 0.83
▸ PDGFRB P09619 1/20 0.83
▸ NQO2 P16083 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pacritinib SCHEMBL30277987 1.00 JAK2 (0.83) JAK2FLT3TYK2CDK2CCNA2
Pacritinib SCHEMBL29395340 0.91 JAK2 (1.00) JAK2FLT3TYK2CDK2CCNA2
Pacritinib SCHEMBL31537559 0.91 JAK2 (1.00) JAK2FLT3TYK2CDK2CCNA2
Pacritinib SCHEMBL30802892 0.91 JAK2 (1.00) JAK2FLT3TYK2CDK2CCNA2
Pacritinib SCHEMBL1108221 0.91 JAK2 (1.00) JAK2FLT3TYK2CDK2CCNA2
Pacritinib SCHEMBL2537450 0.90 JAK2 (0.98) JAK2FLT3TYK2CDK2CCNA2
Pacritinib SCHEMBL2485104 0.90 JAK2 (0.89) JAK2FLT3TYK2CDK2CCNA2
SCHEMBL1108252 0.87 JAK2 (0.92) JAK2FLT3TYK2CDK2CCNA2
Ct-1578 SCHEMBL11895184 0.86 JAK2 (0.82) JAK2FLT3TYK2CDK2CCNA2
SCHEMBL20322432 0.86 JAK2 (0.89) JAK2FLT3TYK2CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2837632-B1 Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO LTD (CN) 2016-05-18 — — EP disclosed
US-20150322084-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT SOBI, INC. 2015-11-12 — — US disclosed
US-9090623-B2 Compound JK12A and preparation thereof LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. (CN) 2015-07-28 — — US disclosed
US-8980873-B2 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt CTI BIOPHARMA CORP. (US) 2015-03-17 — — US disclosed
US-20150065708-A1 COMPOUND JK12A AND PREPARATION THEREOF LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. (CN) 2015-03-05 — — US disclosed
EP-2376499-B1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT CTI BIOPHARMA CORP (US) 2015-02-25 — — EP disclosed
EP-2837632-A1 COMPOUND JK12A AND PREPARATION THEREOF Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. (CN) 2015-02-18 — — EP disclosed
US-20110294831-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT S*BIO PTE LTD. (SG) 2011-12-01 — — US disclosed
EP-2376499-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT S*BIO Pte Ltd (SG) 2011-10-19 — — EP disclosed
WO-2010068181-A8 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT S*BIO PTE LTD (SG) 2011-08-18 — — WO disclosed
WO-2010068181-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT S*BIO PTE LTD (SG) 2010-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065708-A1 COMPOUND JK12A AND PREPARATION THEREOF GRIK5, GRIK2, GRIK1 JAK2 178/4885FLT3 2059/4885IRAK1 469/4885
US-20110294831-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT SLC10A1, IL17A, SLC25A1 JAK2 586/4885FLT3 1851/4885IRAK1 2203/4885
US-20150322084-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT SLC10A1, IL17A, SLC25A1 JAK2 586/4885FLT3 1851/4885IRAK1 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.